Terns Pharmaceuticals is a biopharmaceutical company developing small-molecule single-agent and combination therapy for the treatment of non-alcoholic steatohepatitis and other chronic liver diseases. Its products include TERN-701, a Bcr-Abl tyrosine-kinase inhibitor designed to target the ABL myristoyl pocket, TERN-601, a Glucagon-like peptide-1 receptor agonist for obesity, and other therapies.